<DOC>
	<DOCNO>NCT00000988</DOCNO>
	<brief_summary>To evaluate safety , minimum effective dose ( MED ) , pharmacokinetics efficacy orally administer 2',3'-dideoxy-2',3'-didehydrothymidine ( d4T ) patient AIDS AIDS relate complex ( ARC ) . To establish appropriate dosage regimen d4T employ Phase II III trial . To evaluate effect de-escalating dos d4T marker associate HIV infection . Currently , FDA-approved therapy patient AIDS ARC zidovudine ( AZT ) , drug significant value limit use toxic effect bone marrow . d4T test human , inhibit reproduction HIV ( virus cause AIDS ) laboratory experiment . In study laboratory animal , d4T less toxic blood cell AZT .</brief_summary>
	<brief_title>A Study BMY-27857 Patients With AIDS AIDS Related Complex</brief_title>
	<detailed_description>Currently , FDA-approved therapy patient AIDS ARC zidovudine ( AZT ) , drug significant value limit use toxic effect bone marrow . d4T test human , inhibit reproduction HIV ( virus cause AIDS ) laboratory experiment . In study laboratory animal , d4T less toxic blood cell AZT . A maximum tolerate dose ( MTD ) find Phase I trials date . An MED determine . The daily dose d4T divide 2 portion administer approximately 12 hour apart 10 week . 5 patient receive initial dose level successive group 5 patient enter study low dose level 3 patient precede group successfully complete least 3 week dose show positive effect CD4 cell count p24 antigen level . The initial group patient continue dose dose level additional 94 week long well measure p24 antigen level CD4 cell count . The dose de-escalation scheme continue lack efficacy see 2 5 patient group . Patients assign de-escalating dose level treatment group order enrol . Blood urine sample take regularly check toxic effect therapeutic effectiveness . In dose group , 3 5 patient p24 antigen positive great equal 70 pg/ml , 2 5 patient CDC-defined AIDS .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>AIDS-Related Complex</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Aerosolized pentamidine Pneumocystis carinii pneumonia prophylaxis . TMP/SMX alternative prophylactic agent , 1 DS tablet orally per day . Acute therapy oral acyclovir herpes simplex infection 7 day , provide d4t suspend Symptomatic therapy analgesic , antihistamine , antiemetic , antidiarrheal agent , supportive therapy may administer toxicity deem necessary principal investigator . For therapy fever , aspirin rather acetaminophen use . Concurrent Treatment : Allowed : Transfusion 2 unit pack red blood cell every 3 week grade 3 grade 4 anemia ( see Recommendations Grading Acute Subacute Toxic Effects ( Adults ) ) patient return baseline grade 3 baseline grade 1 grade 4 . Patient must : AIDS AIDS relate complex ( CDC Group IVA CDC Group IVC2 thrush oral leukoplakia ) . Ability provide inform consent . Availability followup least 6 month . Absence active , AIDSdefining opportunistic infection study entry . Exclusion Criteria Coexisting Condition : Patients follow exclude : Active , AIDSdefining opportunistic infection . Intractable diarrhea . History propensity seizure disorder require anticonvulsant control . Any clinical condition opinion investigator would make patient unsuitable unable comply dose requirement . Concurrent Medication : Excluded : Systemic therapy antiretroviral drug ( include AL721 , ddI , ddC , interferon , immunomodulating drug ) investigational drug . Ribavirin . Cytotoxic anticancer therapy . Therapy agent know potent inducer inhibitor drugmetabolizing enzyme , rifampin barbiturate . Systemic maintenance chemoprophylaxis opportunistic infection . Trimethoprim / sulfamethoxazole Pneumocystis carinii infection . Acute therapy ketoconazole thrush . Neurotoxic agent list protocol . Patients follow exclude : Previous intolerance zidovudine ( AZT ) demonstrate transfusion dependent anemia ( transfusion require every 3 week less AZTrelated depression neutrophil &lt; 500 cells/mm3 ) . Life expectancy &lt; 6 month . Prior Medication : Excluded : Any prior therapy opinion investigator would make patient unsuitable unable comply dose requirement . Excluded within 2 week study entry : Therapy agent know potent inducer inhibitor drugmetabolizing enzyme , rifampin barbiturate . Excluded within 1 month study entry : Systemic therapy antiretroviral drug ( include AL721 , interferon , immunomodulating drug , ddI , ddC ) investigational drug . Excluded within 3 month study entry : Ribavirin . Cytotoxic anticancer therapy . Prior Treatment : Excluded : Any prior therapy opinion investigator would make patient unsuitable unable comply dose requirement . Preference : Tolerating zidovudine ( AZT ) time study entry . Active alcohol drug abuse sufficient , investigator 's opinion , prevent adequate compliance study therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1994</verification_date>
	<keyword>Injections , Intravenous</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>